Strides Pharma Science Ltd: A Strong Start to FY 2026

In a remarkable display of financial prowess, Strides Pharma Science Ltd has delivered a robust first quarter for FY 2026. The company reported a revenue of Rs. 11,197 million, alongside an EBITDA of Rs. 2,181 million and an operational PAT of Rs. 1,140 million. This performance underscores the company’s strategic focus on IP-led niche finished dosage formulations and its expansive geographical reach, spanning continents from Africa to North America.

Strides Pharma Science Ltd, headquartered in Bengaluru, India, operates through two primary segments: Pharmaceutical and Bio-pharmaceutical. The company’s diverse product range includes liquids, creams, ointments, soft gels, sachets, tablets, and modified release dosage formats. With manufacturing units in India, Singapore, Italy, the United States, and Kenya, Strides is well-positioned to cater to a global market, particularly in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments.

The company’s financial results reflect its commitment to innovation and quality, which are pivotal in maintaining its competitive edge in the pharmaceutical industry. The strong Q1 performance is a testament to the company’s effective operational strategies and its ability to adapt to market demands.

In addition to its financial achievements, Strides Pharma Science Ltd has made significant corporate developments. The company has announced an amendment to its code of fair disclosure of UPSI, ensuring transparency and compliance with regulatory standards. Furthermore, the company has initiated the allotment of equity shares under its ESOP Scheme, a move that aligns with its strategy to incentivize and retain top talent.

Another noteworthy development is the change in statutory auditors for a material subsidiary in the UK, reflecting the company’s ongoing efforts to enhance its governance and financial oversight.

As of July 29, 2025, Strides Pharma Science Ltd’s stock closed at 922.35 INR on the National Stock Exchange of India, with a market capitalization of 84,810,000,000 INR. Despite a challenging year with a 52-week low of 513.05 INR in April 2025, the company’s recent performance indicates a positive trajectory.

Investors and stakeholders can look forward to continued growth and innovation from Strides Pharma Science Ltd as it leverages its global presence and expertise in niche pharmaceuticals to drive future success.